Search results
Results from the WOW.Com Content Network
The last reason to buy this stock today is that its balance sheet is looking as good as it gets in biotech. At the end of the first quarter, it had around $2.1 billion in cash, cash equivalents ...
CRSP Market Cap data by YCharts. 3. Intensive competition. The success of CRISPR Therapeutics will depend on its ability to bring multiple new drugs to the market to support a more viable business ...
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and CRISPR Therapeutics wasn’t one of them. The 10 stocks that ...
*Stock Advisor returns as of October 7, 2024. Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex ...
On Nov. 21, shares of CRISPR Therapeutics (NASDAQ: CRSP) were down 47% from a peak they reached in March. After all, it's been less than a year since regulators in the U.S. and E.U. approved its ...
CRISPR Therapeutics (NASDAQ: CRSP) isn't a stock that's wanting for reasons to invest. Per the company's presentation at the American Society of Hematology's (ASH) annual meeting on Dec. 9, the ...
Crispr's stock has started to lose momentum after blasting higher earlier this year. Is the market correcting a prior mistake, or is this dip a buying opportunity?
For premium support please call: 800-290-4726 more ways to reach us